BVS vs LIN · rev $573.3M vs P/E 34, rev $33.99B
Bioventus Inc (BVS) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Bioventus Inc (BVS) is a medical devices company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported BVS revenue for 2024-12-31 was $573.3M. Net income was -$43.8M. Revenue was up 11.9% from 2023-12-31 to 2024-12-31. BVS currently screens at market cap $495.1M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
BVS currently screens at market cap $495.1M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the BVS and LIN stock pages for the full models.
Not investment advice.